/

Società

Ge

Non verificato

Genmab

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaOncologiaSalute

5 comunicati stampa

Guarda tutti i comunicati

11/06/2026

Oncologia

Salute

Medicina - Varie

Scienza

Farmaceutica

Biotecnologia

Eventi

Industria

Genmab Presents EPCORE® FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Across Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Patients

Fonte

Emittente

1.00

0

18/10/2025

Scienza

Medicina - Varie

Biotecnologia

Sanità

Salute

Farmaceutica

Oncologia

Industria

Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer

Fonte

Emittente

1.00

0

07/08/2025

Scienza

Biotecnologia

Farmaceutica

Oncologia

Sanità

Salute

Medicina - Varie

Industria

Genmab Announces Phase 3 EPCORE® FL-1 Clinical Trial Met Dual Primary Endpoints in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL)

Fonte

Emittente

1.00

0

15/06/2025

Scienza

Biotecnologia

Farmaceutica

Oncologia

Salute

Medicina - Varie

Industria

Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT)

Fonte

Emittente

1.00

0

17/03/2025

Eventi

Fiere

Industria

Scienza

Igiene alimentare

Medicina - Varie

Biotecnologia

Salute

Farmaceutica

Sanità

Oncologia

Investigational Rinatabart Sesutecan (Rina-S®) Continues to Show Encouraging Antitumor Activity in Patients with Advanced Ovarian Cancer

Fonte

Emittente

1.00

0

Seguaci

0

Compatibilità

0